Business
Know the Business
Star Health is India's only pure-play listed health insurer at scale: ₹20,369 crore in gross written premium, 31.3% retail market share, and 20 years of underwriting data on 2.8 crore lives that no entrant can replicate quickly. The central tension is that the very thing that makes the franchise valuable — an 830,000-agent retail distribution network reaching Tier 2 and Tier 3 India — also makes the economics volatile when medical inflation outpaces annual pricing action. FY2026 marks the inflection: combined ratio returned to 98.8% (below 100% for the first time in two years), underwriting profit turned positive at ₹206 crore, and FY2027 begins with pricing corrections flowing through 80% of the renewal book.
GWP FY2026 (₹ Cr)
Retail Health Market Share (%)
Combined Ratio FY2026 (%)
Solvency Ratio
PAT FY2026 (₹ Cr)
GWP Growth YoY (%)
1. How This Business Actually Works
The underwriting profit or loss is not the only score. The investment float is often bigger.
Health insurance is a premium-funded protection business with two distinct profit engines. Policyholders pay annual premiums in advance; the insurer pools those payments, invests the accumulated float, and draws on it to pay claims over the policy period. A structural surplus emerges because premiums arrive upfront but claims arrive weeks to months later — and in India's current rate environment, the float earns 7.7–8% per annum on ₹17,898 crore of invested assets.
The Economic Engine
Why Retail Health Is Different from Group Health
This distinction is the most important structural fact about Star Health's positioning.
Group health (corporate policies): the employer buys coverage for all employees. The insurer is selling to a procurement team that negotiates on price. Adverse selection is severe — employees with known conditions are included. Loss ratios in group health run 80–95%. Star Health deliberately cut its group share from 9% of GWP (FY2025) to 5% in FY2026, and the group loss ratio dropped from 94.6% to approximately 76% as a result.
Retail health (individual and family floater): the individual chooses to buy based on perceived need. Healthier people self-select in at the time of purchase. First-year loss ratios are structurally lower. Annual renewals at actuarially-justified prices (not market-bid prices) prevent the undercutting cycle that plagues group. Star's retail loss ratio in FY2026 was 64.8% — versus 68.7% blended.
The ratio that encodes this difference:
The deliberate retreat from group health was a bet that retail loss ratio discipline is worth the revenue sacrifice. FY2026 validates it.
The Agency Distribution Model: Claimed Moat, Real Friction
Star Health uses 830,000+ licensed agents as its primary distribution channel (83% of GWP). The agent network is the source of both the business's resilience and its cost structure.
Why it is a moat: An agent who has placed ten families with Star Health creates a renewal income stream (trail commission) that is sticky. Each renewal requires zero incremental acquisition effort for the insurer — the agent manages the relationship. This is why Star's renewal retention rate is 99% (value basis) and 86–87% volume — best-in-class among SAHIs. The 20-year trust relationship between Star's brand and agents in Tier 2–3 towns is not easily replicated by a new entrant with a digital-first model.
Why it is also a cost: Agent commissions represent approximately 17% of GWP at current run rates. IRDAI's Expense of Management (EOM) cap of 35% of GWP limits how much Star can spend across commissions + salaries + technology + marketing combined. Star was the only SAHI operating within EOM limits as of FY2026 — competitors were non-compliant with the March 2026 deadline.
The leverage: As the renewal book compounds, the incremental cost per rupee of renewal premium declines. A ₹10,000 premium renewed in year three costs the insurer roughly 5% of the year-one acquisition expense. This is the agency leverage story: 93% fresh premium from new-to-insurance customers (FY2026) means the active book is skewed toward first-year (higher-cost) customers, but those customers become high-margin renewal policies in years 2–5.
The agency moat has one key vulnerability: if IRDAI mandates a line-of-business-level EOM cap (allowing diversified insurers to cross-subsidize Retail Health acquisition costs from motor and fire margins), Star's cost advantage narrows. Management confirmed regulators are reviewing this but no decision has been announced.
2. The Playing Field
Star Health is roughly 3× the size of its nearest listed SAHI peer. But scale in a structurally fragmented market is only valuable if it translates into underwriting discipline others cannot match.
Star Health trades at 1.5× GWP — a discount to every listed peer. The discount reflects: (a) the FY2025 loss ratio spike that burned investor confidence, (b) Star's lower ROE (9.2% FY2025 vs ICICI Lombard's 17%), and (c) investor uncertainty about whether the FY2026 combined ratio improvement is structural or seasonal.
What "good" looks like in this industry: combined ratio below 100% consistently, loss ratio under 70%, solvency above 2×, and retail share growing faster than the industry. Star meets all four in FY2026. The question is whether it sustains them.
Niva Bupa's retail loss ratio of 59.4% is materially better than Star's 64.8%. This is either a product mix advantage (Niva Bupa skews younger demographics) or a nascent book effect (younger book = lower frequency). As Niva Bupa's book seasons, its loss ratio may converge toward Star's range — but two more annual filings are required to distinguish aging from structural superiority.
SAHI vs Diversified GI — the structural shift: SAHIs grew at 16% in FY2025 vs approximately 5% for diversified GI players in health. SAHIs now hold 57.63% of the retail health market. The specialist model — deep underwriting focus, 20 crore+ claims records, no cross-subsidization pressures — is outcompeting generalists. This is a structural tailwind for Star, not a cyclical one.
3. Is This Business Cyclical?
Health insurance is one of the least cyclical financial businesses — but it is not acyclical. Three distinct cycle types matter.
The Medical Inflation Cycle
Medical costs in Indian hospitals rise 10–15% annually (Aon and Willis Towers Watson both cited 12–13% for 2026). This is the dominant cycle driver. When premium increases lag medical inflation by even one year, loss ratios deteriorate. When pricing catches up, they recover. The FY2021–FY2023 COVID distortion was an extreme version of this: hospitalisations spiked suddenly, loss ratios hit 94.4% in FY2021, and only two years of disciplined repricing returned the business to sub-100% combined ratios.
The 100% line is the critical threshold. Above it, the insurer earns nothing from underwriting and must rely entirely on investment income to deliver any ROE. Below it, each additional rupee of GWP generates both underwriting margin and investment income — the compounding that justifies premium multiples.
The Pricing Action Lag
Annual price hikes take 12–24 months to fully flow through into net earned premium (NEP). Premiums are collected on the policy start date, but NEP is recognised day-by-day over the policy period. A price hike in October takes 12 months to be 100% earned. The FY2025 loss ratio spike to 70.3% was partly a function of frequency-driven claims rising faster than earnings could absorb prior-year price corrections. Star took cohort-based hikes of 20–40% on specific high-loss segments starting Q4 FY2024 — and as of Q4 FY2026, 80% of the book has been repriced.
The COVID Distortion
FY2021–FY2022 were structurally abnormal. COVID-related hospitalisations created a claims surge with zero pricing power (IRDAI restricted premium hikes during the pandemic). The combined ratio hit 122% in FY2021. This episode is frequently misread as evidence that Star's business model is flawed; every health insurer globally saw similar or worse deterioration. The model recovered through pricing within two years — a demonstration of the annual renewal mechanism's effectiveness.
The GST Exemption Demand Shock (FY2026)
The GST Council exempted retail health premiums from 18% GST effective September 2025. The immediate effect: retail health industry grew 30.2% YoY in H2 FY2026 versus 11.2% for broader non-life. This is a one-time demand-level shift. Once anniversaried (H2 FY2027), the growth rate normalises to the structural 15–20% range. Star's management guides for sustainable high-teen GWP growth through proprietary channels.
FY2026 is the first year Star combines two positives simultaneously: above-market GWP growth (37% fresh retail on N-basis) AND improving loss ratio (down 200 bps). The 93% new-to-insurance mix (customers who never had coverage before) is why this works: genuinely new customers have lower disease burden at entry and sustain the risk pool rather than deteriorating it.
4. The Metrics That Actually Matter
Six numbers tell you most of what you need to know about Star Health's health in any given quarter.
Combined Ratio Components Over Time
The expense ratio (orange) has been remarkably stable at 30–31% across the entire history. The volatility is entirely in the loss ratio (red). Management has tight cost control; the underwriting skill gap is where alpha is generated or destroyed.
GWP Growth Trajectory
GWP has compounded at approximately 22% annually from FY2018 to FY2026. The deceleration to 10% in FY2025 reflected deliberate portfolio recalibration (cutting group health). FY2026's 16% recovery on a larger base — while improving loss ratios — is the first year these two have moved together.
Profitability: The PAT Story
The FY2021–FY2022 losses are the COVID episode. The recovery to ₹845 crore PAT in FY2024 marked a return to pre-COVID trajectory. The FY2025 dip to ₹646 crore (statutory Indian GAAP; IndAS-restated comparable: ₹787 crore) reflects the loss ratio cycle — not structural deterioration. FY2026 actual PAT of ₹911 crore (IndAS; ₹1,222 crore normalized at 8% investment yield, stripping ₹127 crore MTM equity loss) marks the trajectory resumption. Chart above uses statutory Indian GAAP for FY2018–FY2025; FY2026 is IndAS — management cited 16% YoY PAT growth using the IndAS-restated FY2025 base of ₹787 crore.
5. What Is This Business Worth?
Health insurer valuation is not a simple P/E exercise. The two dominant frameworks are Price/GWP and Price/Book — and both carry specific limitations.
Framework 1: Price/GWP
The simplest check. Market cap divided by annual gross written premium.
Star trades at 1.5× GWP — a discount to every listed peer. The discount is partly justified by the FY2025 combined ratio above 100%. A re-rating to 2.0× GWP would imply a market cap of ₹40,738 crore — 33% above current levels — but that re-rating requires the FY2026 combined ratio improvement to prove durable across at least one more year, including Q1 FY2027, where every prior Q1 has printed above 102%.
Framework 2: Price/Book
Star's book value per share was ₹129.04 (FY2026, statutory). At ₹520, the stock trades at approximately 4.03× book. The Gordon Growth Model justification for that multiple requires ROE of approximately 21% (cost of equity 14%, long-run growth 12%). Star has never achieved 21% ROE: the FY2024 peak was 13.3%, and FY2026 IndAS ROE was 12.5% (7.6% on statutory basis).
What ROE Must the Business Earn to Justify the Multiple?
Management's stated target is mid-teen ROE (15–16%). FY2026 IndAS ROE came in at 12.5% (statutory: 7.6%) — meaningfully below the 21% the current 4.03× book multiple demands. Sustaining loss ratio improvement (64–66% retail) while growing GWP at 18–20% is the path to the target; the 4.03× book is justifiable at 15%+ ROE and expensive at 9–10% ROE.
The India Penetration Story
Health insurance penetration in India stands at approximately 0.36% of GDP vs 2%+ in developed markets. The number of lives covered under retail health reached 6 crore by March 2025 — growing at 7.7% annually. The GST exemption (effective H2 FY2026) is the first structural demand-side catalyst since Ayushman Bharat (2018). At the current growth trajectory, the retail health premium market doubles within 5–6 years — and Star, as the market leader with 31.3% share, is positioned to grow on the base effect alone.
The penetration story is real and in the consensus — every analyst covering Star Health knows about India's underpenetration. The differentiated question is: at what combined ratio does GWP growth actually compound into shareholder value? The answer is approximately 96–97% combined ratio — 200–300 bps below current levels. That is the work management needs to do.
6. What I'd Tell a Young Analyst
The single most important thing to track: the retail loss ratio on a trailing-twelve-month basis, comparing each quarter to the same quarter last year. Seasonality is real (Q2 is the worst quarter — monsoon disease season), so YoY comparisons are more useful than sequential. If the retail loss ratio is trending from 68% toward 65%, the investment thesis is working. If it is reversing toward 70%+, pricing discipline has broken.
What the market may be mis-weighing: The market treats Star Health's below-100% combined ratio in FY2026 as potentially temporary — one good year after two bad ones. But the structural work is deeper than a single annual pricing cycle: 80% of the book repriced, cohort-based pricing (different hikes for claimants vs non-claimants), group health deliberately cut to 5%, SME group (which has better loss ratios than large-corporate group) at 78% of the corporate book. If this proves a durable operational shift, the conditions for a re-rating toward 2.0× GWP would be met.
The risk the market has right: Medical inflation at 12–13% annually is structural, not cyclical. Star's pricing action must permanently run at medical inflation-plus to maintain loss ratio stability. In years where pricing is even one quarter late or light, the loss ratio spikes by 3–5 percentage points and ROE collapses. The FY2025 spike from 66.4% to 70.3% loss ratio happened in a single year. This binary sensitivity is why the stock has traded at a persistent discount to international health insurer multiples.
The agent network — don't underestimate the renewal engine: 99% value-based renewal retention is the most underappreciated number in this story. Every year that passes, a larger share of Star's GWP requires zero incremental customer acquisition cost. The leverage builds silently in the background, and it is the mechanism by which the combined ratio can improve even while fresh acquisition costs remain elevated.
One thing to verify every quarter: new-to-insurance customer mix. As long as this stays above 90%, Star is genuinely expanding the insured base rather than cannibalising portability customers. When it drops below 85%, the growth quality story breaks down.
The one risk that is harder to model: composite licensing. If IRDAI allows life insurers to sell health products under a single licence, the competitive landscape changes structurally. Star has 20 years of standalone health focus and 2.8 crore lives of underwriting data — but a well-capitalised life insurer entering retail health with bancassurance distribution would be a genuine threat to growth, not loss ratios. Watch IRDAI regulatory announcements carefully.